Walt Disney Co. said Josh D’Amaro, a 28-year-veteran of the company, will succeed Bob Iger as chief executive officer of the entertainment giant effective March 18. Ed Ludlow reports on Bloomberg Television. (Source: Bloomberg)
Walt Disney Co. said Josh D’Amaro, a 28-year-veteran of the company, will succeed Bob Iger as chief executive officer of the entertainment giant effective March 18. Ed Ludlow reports on Bloomberg Television. (Source: Bloomberg)
Grandbrothers/iStock Editorial via Getty Images Shares of Nano-X Imaging ( NNOX ) added ~12% in the premarket on Tuesday after the U.S. FDA cleared a new cloud-enabled image enhancement functionality for its digital X-ray systems, Nanox.ARC and Nanox.ARC X. The decision marks a significant step in making its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems among the industry’s leading diagn...
Grandbrothers/iStock Editorial via Getty Images Shares of Nano-X Imaging ( NNOX ) added ~12% in the premarket on Tuesday after the U.S. FDA cleared a new cloud-enabled image enhancement functionality for its digital X-ray systems, Nanox.ARC and Nanox.ARC X. The decision marks a significant step in making its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems among the industry’s leading diagnostic solutions, the Israeli MedTech firm said in a statement on Tuesday. The company added that the image enhancement capability known as TAP2D allows radiologists to generate a 2D image directly from a tomosynthesis scan without any added complexity and disruption to clinical workflow. The approval “would allow the Nanox.ARC to serve as a standalone primary imaging solution as it already does in Europe under our CE Mark certification,” CEO Erez Meltzer noted. Nano-X ( NNOX ) expects to launch the enhancement software as part of its ongoing commercial rollouts of imaging improvements. More on Nano-X Imaging Nano-X Imaging Remains Underwhelming Despite Recent Wins Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript NANO-X IMAGING launches $15M stock offering Nano-X jumps as 2026 outlook beats consensus Seeking Alpha’s Quant Rating on Nano-X Imaging
Global Medical REIT ( GMRE ) on Tuesday announced a name change to Chiron Real Estate, effective as of 12:01 AM ET on February 23. The ticker symbol will change to XRN on the NYSE. "After spending the last six months evaluating and redefining our strategy, we are rebranding to better align with our new mission," said CEO Mark Decker. "Chiron (Kai-ron), a figure from Greek mythology known for his k...
Global Medical REIT ( GMRE ) on Tuesday announced a name change to Chiron Real Estate, effective as of 12:01 AM ET on February 23. The ticker symbol will change to XRN on the NYSE. "After spending the last six months evaluating and redefining our strategy, we are rebranding to better align with our new mission," said CEO Mark Decker. "Chiron (Kai-ron), a figure from Greek mythology known for his knowledge and skill with medicine, was highly revered as a teacher and tutor, and we believe Chiron embodies our refreshed mission," added Decker. The ticker symbol for preferred stocks will change to XRN PrA from GMRE PrA and to XRN PrB from GMRE PrB. More on Global Medical REIT Global Medical REIT: Buy This 9% Yield While The Market Ignores Value Global Medical REIT: Time To Buy As The Need For Outpatient Care Could Grow GMRE.PR.B: An 8.00% Preferred Stock IPO From Global Medical REIT AEW Capital exits six REITs in Q3, initiates position in American Tower Global Medical prices $50M in new preferred stock offering priced at $25.00 a share
Now we get into the meat of this thing - Scotland's inability to contend in a Six Nations and the factors that hold them back. Everybody can see them. Every year they're played out in an excruciating loop, be it spring or autumn or both. In November, Scotland were poor enough to fall 17-0 behind against New Zealand and yet good enough to make it 17-17 thereafter, before falling away at the end. A ...
Now we get into the meat of this thing - Scotland's inability to contend in a Six Nations and the factors that hold them back. Everybody can see them. Every year they're played out in an excruciating loop, be it spring or autumn or both. In November, Scotland were poor enough to fall 17-0 behind against New Zealand and yet good enough to make it 17-17 thereafter, before falling away at the end. A week later they were dominant in going 21-0 ahead against Argentina and then hapless in conceding 33 points in the second half and losing. They were booed that day at Murrayfield. It's a recurring theme. The quality of Scotland's squad is undoubted but the frailties are impossible to miss. In last season's Six Nations they fell 17-0 behind against Ireland and couldn't find a way back. In the loss to England they didn't score for an hour. Against Wales they had 35 points and victory in the bag after 49 minutes but shipped 21 unanswered points from there. They hung on to win, just about. These moments torment Scotland. There's brilliance but there's also painful weakness - soft beginnings to Tests, panic when well on top, overplaying, error counts, poor discipline adding pressure, players going off script, chances butchered, lack of mental resilience. Schoeman doesn't shy away from any of that. He says the anger of losing those games in the autumn "turns into fuel". For example? "When the momentum shift goes away, limit those mistakes," he says. "Our 22-metre conversion rate has to be better. Our mental resilience and momentum in the last 20 minutes has to be better as well. "We have to be better at closing games out. And it's something we work with. Different scenarios. Yellow cards, momentum shifts, external decisions that go against you. What's our process? Let's go to that anchor mindset."
Tom Werner/DigitalVision via Getty Images Xeris Pharmaceuticals' ( XERS ) shares have surged nearly 100% year-over-year (YoY) as a result of both strong and accelerating commercial revenue growth, improving operational discipline, and positive results from its pipeline. Today, Xeris represents more than just a development-stage biotechnology company; it has transformed into a commercial specialty ...
Tom Werner/DigitalVision via Getty Images Xeris Pharmaceuticals' ( XERS ) shares have surged nearly 100% year-over-year (YoY) as a result of both strong and accelerating commercial revenue growth, improving operational discipline, and positive results from its pipeline. Today, Xeris represents more than just a development-stage biotechnology company; it has transformed into a commercial specialty pharmaceutical business with several successful products and a clear pathway to further growth. After the substantial rally, I believe there may be more upside potential for the stock, as the market may not have fully priced in the growth potential of its blockbuster drugs. Recorlev Drives Growth Xeris Pharma Investor Relations Xeris' preliminary financial results for the fourth quarter and full fiscal year 2025 highlight that Xeris achieved record total revenues of approximately $292 million, which is higher than previously guided estimates. This represents growth of 44% compared to last year. Recorlev revenue is expected to be $45 million in Q4, which would represent an increase of 22% from Q3 2025 (see above). Management continues to see sustained strength across its three commercial products (Gvoke, Recorlev, Keveyis) and also reported positive adjusted EBITDA for each four quarters during 2025. Current Pipeline Xeris Pharma Investor Relations Xeris currently specializes in markets with unmet medical needs, such as endocrinology and rare diseases. The first commercialized product from Xeris is Gvoke . This emergency rescue medication treats severe hypoglycemia, an extremely serious, life-threatening condition suffered by people with diabetes when their blood sugar levels drop below normal ranges (hypoglycaemia). Previously, administering glucagon from rescue kits required mixing powder and liquids by a bystander prior to administering the glucagon. However, such preparation often leads to mistakes or incorrect usage. Gvoke is able to eliminate this preparation step, by ...
(RTTNews) - The Walt Disney Company (DIS) Board has elected Josh D'Amaro to become Chief Executive Officer, effective at the Annual Meeting on March 18, 2026, when he will succeed CEO Robert Iger. The Board also intends to appoint D'Amaro as a director immediately following that meeting. D'Amaro has served as Chairman of the Disney Experiences segment since 2020, and prior to that was President of...
(RTTNews) - The Walt Disney Company (DIS) Board has elected Josh D'Amaro to become Chief Executive Officer, effective at the Annual Meeting on March 18, 2026, when he will succeed CEO Robert Iger. The Board also intends to appoint D'Amaro as a director immediately following that meeting. D'Amaro has served as Chairman of the Disney Experiences segment since 2020, and prior to that was President of Walt Disney World Resort. He joined the company in 1998. Upon transition, Bob Iger will continue to serve as Senior Advisor and a member of the Disney Board until his retirement from the company on December 31, 2026. Dana Walden, Co-Chairman of Disney Entertainment, has been named President and Chief Creative Officer of The Walt Disney Company, also effective March 18. In pre-market trading on NYSE, Walt Disney shares are up 1.06 percent to $105.65. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The odds appeared to be shifting against French far-right leader Marine Le Pen at her appeal trial over a conviction for embezzling European Union funds, after a prosecutor said he’d seek to keep election bans against several defendants in the case. Advocate general Thierry Ramonatxo, a lead prosecutor in the case, said on Tuesday he would recommended that the Paris appeals court confirm most init...
The odds appeared to be shifting against French far-right leader Marine Le Pen at her appeal trial over a conviction for embezzling European Union funds, after a prosecutor said he’d seek to keep election bans against several defendants in the case. Advocate general Thierry Ramonatxo, a lead prosecutor in the case, said on Tuesday he would recommended that the Paris appeals court confirm most initial convictions against defendants of the National Rally and would also request election bans — falling short of saying who would be targeted. He said prosecutors would get into the specifics, including the identities, later in the afternoon. Le Pen is battling to overturn a five-year election ban ordered in March that would cut her out of the 2027 presidential race if confirmed. An appellate decision is expected by the summer. Le Pen stands accused of misusing about €474,000 ($559,320) between 2009 and 2016 when she was a member of the European Parliament to hire aides and encouraging other lawmakers from her party to divert millions more euros. The widely awaited speech gives Le Pen a first glimpse of how convincing she has been during an appellate trial that began with her striking a conciliatory tone. Her slight shift in defense strategy on appeal to avoid being left out of the running in Spring 2027 has included insisting she had “no sense” or intention of breaking any rules and saying that none have been since. Still, in his initial remarks on Tuesday, Ramonatxo noted that Le Pen continued to broadly deny any wrongdoing. In court testimony last month, she “formally” contested being at the heart of a system to embezzle the funds. Read More: Le Pen Denies Any Sense She Committed a Crime Over EU Funds The appellate ruling will ultimately shape the political battle to replace President Emmanuel Macron as he nears the last year of his final term. If Le Pen loses her appeal and the full ban is confirmed, the National Rally is expected to field 30-year-old Jordan Bardella as...
coldsnowstorm/iStock Unreleased via Getty Images Walt Disney's ( DIS ) Q1 2026 earnings were not received well by the market with the stock down by more than 7% on the day following the release. Unfortunately, the report seems to be overshadowing more challenges ahead and if that is the case then the daily share price drop would be only the start. I have warned against these risks before , but thi...
coldsnowstorm/iStock Unreleased via Getty Images Walt Disney's ( DIS ) Q1 2026 earnings were not received well by the market with the stock down by more than 7% on the day following the release. Unfortunately, the report seems to be overshadowing more challenges ahead and if that is the case then the daily share price drop would be only the start. I have warned against these risks before , but this quarter has cemented some of my fears and it seems that Disney's stock is in for more volatility and downward pressure in this calendar year. Thus the base case scenario for Disney's stock remains for it to continue to muddle through around $100 a piece in the coming year with the risk of a sharp decline if the aforementioned two issues are not properly addressed. Data by YCharts Some Positives From Disney's Q1 Before we dive into the major problems outlined in the Q1 report, we should mention some of the positives during the quarter. These developments could be easily mistaken as a reason to be optimistic about the stock by Disney's diehard fans. Especially, when combined with the seemingly low earnings multiple of the stock. Data by YCharts First and foremost is Disney's management expectation that they could deliver double-digit adjusted earnings per share growth in the current fiscal year. Based on the nuances provided, however, it seems that this growth is anticipated to be skewed towards the second half of the fiscal year. The first pillar of EPS growth is expected to be the Entertainment segment where according to Disney's management theatrical releases and sustained growth in streaming would result in double-digit operating income growth. For fiscal 2026, we continue to expect double-digit Entertainment segment operating income growth weighted to the second half of the year, driven by our theatrical release slate and continued growth from our SVOD services. Q2 Entertainment segment operating income is expected to be roughly comparable to Q2 last year. Source: DIS ...
champc/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 information technology stocks that are regarded as cheap high flyer stocks according to SA grading system. Each of these stocks is listed according to the highest momentum grade along with their valuation grade. The list includes companies from the technolo...
champc/iStock via Getty Images As earnings season ramps up and geopolitical tensions keep affecting the markets, below is a list of the top 10 information technology stocks that are regarded as cheap high flyer stocks according to SA grading system. Each of these stocks is listed according to the highest momentum grade along with their valuation grade. The list includes companies from the technology sector with varying market capitalizations, ranging from small-cap firms to industry giants. The list is topped by Comtech Telecommunications ( CMTL ), CPS Technologies ( CPSH ), and Hut 8 ( HUT ), all carrying an A+ momentum grade. Hut 8 ( HUT ) stands out with a Strong Buy quant rating of 4.93 and a market cap of $6.07B. Other notable companies in the top ten include Micron Technology ( MU ), which boasts the largest market capitalization at $492.75B and a Strong Buy rating of 4.99. Vistance Networks ( VISN ) and Viasat ( VSAT ) also earned A+ momentum grades, with Viasat ( VSAT ) offering the strongest valuation grade among the A+ momentum stocks at A-. Momentum and valuation grades are given on a scale from A+ to F. An A+ momentum grade represents the highest flyer stock with the best momentum, while an A+ valuation grade indicates the most undervalued or “cheapest” stock. A lower valuation grade suggests the stock may be more overvalued relative to its peers. Here is the list: Comtech Telecommunications ( CMTL ), Momentum: A+, Valuation: B CPS Technologies ( CPSH ), Momentum: A+, Valuation: B- Hut 8 ( HUT ), Momentum: A+, Valuation: B Micron Technology ( MU ), Momentum: A+, Valuation: B- Vistance Networks ( VISN ), Momentum: A+, Valuation: B+ Viasat ( VSAT ), Momentum: A+, Valuation: A- Kimball Electronics ( KE ), Momentum: A, Valuation: A Netlist ( NLST ), Momentum: A, Valuation: B ON24 ( ONTF ), Momentum: A, Valuation: B- Photronics ( PLAB ), Momentum: A, Valuation: A- Tech ETFs: ( VGT ), ( XLK ), ( IYW ), ( FTEC ), ( IXN ), and ( RSPT ) More on IT stocks The Magn...
The Met police have said they are considering whether to launch a criminal investigation into Peter Mandelson after fresh disclosures from the Jeffrey Epstein files. Which laws could he potentially be accused of breaking and on what basis? What could Mandelson be accused of? The Met have said they have received a number of reports relating to possible misconduct in public office. The SNP and Refor...
The Met police have said they are considering whether to launch a criminal investigation into Peter Mandelson after fresh disclosures from the Jeffrey Epstein files. Which laws could he potentially be accused of breaking and on what basis? What could Mandelson be accused of? The Met have said they have received a number of reports relating to possible misconduct in public office. The SNP and Reform UK reported Mandelson to the police to investigate any possible offences. Emily Thornberry, the Labour chair of the foreign affairs select committee, also said she believed his apparent actions should merit a criminal inquiry. What were the revelations that led to this point? The new disclosures from the Epstein files appeared to suggest Mandelson sent emails to the late sex offender containing confidential information that the government was receiving to deal with the global financial crash while he was business secretary under Gordon Brown. They are thought to have included: Peter Mandelson apologises for Epstein association in sudden U-turn Read more A confidential UK government document outlining £20bn in asset sales. Mandelson claiming he was “trying hard” to change government policy on bankers’ bonuses. An imminent bailout package for the euro the day before it was announced in 2010. A suggestion that the JPMorgan boss “mildly threaten” the chancellor. What is required to prove misconduct in public office? A 2004 court of appeal case said the constituent elements of the common law offence were: A public officer acting as such. [Who] wilfully neglects to perform his duty and/or wilfully misconducts himself. To such a degree as to amount to an abuse of the public’s trust in the office holder. Without reasonable excuse or justification. The offence has been widely criticised for being ill-defined and lacking clarity. It is in the process of being replaced by a new statutory offence. The current offence carries a maximum sentence of life imprisonment. According to a Spo...
Arko Petroleum Corp. , the fuel wholesaler subsidiary of convenience store firm Arko Corp. , is seeking to raise as much as $210 million in an initial public offering that could value the company close to $1 billion. The Richmond, Virginia-based fuel distributor plans to market 10.5 million shares for $18 to $20 each, according to a filing with the US Securities and Exchange Commission Tuesday. At...
Arko Petroleum Corp. , the fuel wholesaler subsidiary of convenience store firm Arko Corp. , is seeking to raise as much as $210 million in an initial public offering that could value the company close to $1 billion. The Richmond, Virginia-based fuel distributor plans to market 10.5 million shares for $18 to $20 each, according to a filing with the US Securities and Exchange Commission Tuesday. At the top of that range, Arko Petroleum would have a market value of about $910 million based on the outstanding shares listed in its filing. Arko Petroleum operates in more than 30 US states and delivers fuel to over 1,100 Arko convenience store gas stations including brands like Fas Mart and E-Z Mart. The firm also distributes fuel to over 2,000 third-party gas stations in the US and distributes wholesale fuel to unstaffed fueling locations serving commercial fleets. For the latest news on equity capital markets activity in the US, Canada and Latin America, follow the channel or visit NI BFWECMUS . To subscribe to ECM Watch , Bloomberg’s daily roundup of news from around the region, click here . Net income attributable to Arko Petroleum fell to $24.7 million on revenue of $4.27 billion for the nine months ended Sept. 30, 2025, from $32.7 million on revenue of $4.92 billion a year earlier, according to the filing. The firm delivered 1.5 billion gallons of fuel in the first nine months of 2025, compared to 2.1 billion gallons in the 2024 full-year period. Arko Corp. is expected to maintain a majority of the voting power in Arko Petroleum after the listing, the filing shows. Shares of Arko Corp. gained 7% in premarket trading on Tuesday. The firm’s shares fell 31% in 2025. Arko Petroleum plans to pay a quarterly dividend of $0.50 per share after the listing. The offering pricing date is Feb. 11, according to terms seen by Bloomberg News. The offering is being led by UBS Group AG , Raymond James Financial Inc. and Stifel Financial Corp. The company is expected to trade on the ...
Stock index futures were higher on Tuesday as investors looked to build on recent gains. Here are the four stocks to watch on the day: Merck ( MRK ) shares fell ~0.7% in premarket trading after the drugmaker issued a full-year 2026 outlook that came in below Wall Street expectations. The Rahway, New Jersey-based company forecasts adjusted EPS of $5.00 to $5.15 on revenue of $65.5 billion to $67 bi...
Stock index futures were higher on Tuesday as investors looked to build on recent gains. Here are the four stocks to watch on the day: Merck ( MRK ) shares fell ~0.7% in premarket trading after the drugmaker issued a full-year 2026 outlook that came in below Wall Street expectations. The Rahway, New Jersey-based company forecasts adjusted EPS of $5.00 to $5.15 on revenue of $65.5 billion to $67 billion for 2026. HP ( HPQ ) shares dropped 2.6% in early action after the company announced that Enrique Lores has stepped down as CEO and a member of its board of directors, effective immediately. Board member Bruce Broussard will serve as interim CEO. Separately, PayPal announced Lores would take the top job at the payments giant, replacing Alex Chriss. Pfizer ( PFE ) shares fell 4.6% in premarket trading after the company reaffirmed its full-year outlook, indicating a revenue contraction for 2026 amid a nearly $1.5 billion impact attributed to some of its products facing loss of market exclusivity. However, the New York-based pharma giant beat expectations with its Q4 2025 results. PayPal ( PYPL ) stock tumbled 16.9% before the opening bell after the fintech issued disappointing guidance, delivered weaker-than-expected Q4 earnings and revenue, and replaced its CEO. The board replaced Alex Chriss, who led PayPal for two and a half years. More Related Stories HP Inc.: A Share Cannibal Trading At Cycle Lows PayPal: Golden Buying Opportunity Before Q4 Earnings Pfizer: Buyer Beware, The Risk Outweighs The Reward PayPal stock sinks after Q4 earnings, guidance disappoint; CEO exits Pfizer projects annual revenue decline amid $1.5B hit from patent cliffs
is a senior reviewer with over twenty years of experience. She covers smart home, IoT, and connected tech, and has written previously for Wirecutter, Wired, Dwell, BBC, and US News. Posts from this author will be added to your daily email digest and your homepage feed. All the smart home news, reviews, and gadgets you need to know about Google Home users, your long nightmare is over. The platform ...
is a senior reviewer with over twenty years of experience. She covers smart home, IoT, and connected tech, and has written previously for Wirecutter, Wired, Dwell, BBC, and US News. Posts from this author will be added to your daily email digest and your homepage feed. All the smart home news, reviews, and gadgets you need to know about Google Home users, your long nightmare is over. The platform has finally added support for buttons. The release notes for a February 2 update state that several new starter conditions for automations are now available, including “Switch or button pressed.” Smart buttons are physical, programmable switches that you can press to trigger automations or control devices in your smart home, such as turning lights on or off, opening and closing shades, running a Good Night scene, or starting a robot vacuum. A great alternative to voice and app control when you want to control multiple devices, smart buttons are often wireless and generally have several ways to press them: single press, double press, and long press, meaning one button can do multiple things. Most smart home platforms support using buttons to control connected devices, including Apple Home, Amazon Alexa, Samsung SmartThings, and Home Assistant. With the arrival of Matter, an interoperability standard for connected devices, it’s become easier to control all of your devices with buttons (called a generic switch in the Matter spec). However, Google Home has frustratingly not had this functionality — until now. The release notes specify that the following function is now supported in the Google Home app (but not by Ask Home or Help Me Create, Google’s Gemini for Home-powered automation features): “Switch or button is pressed**: e.g. “When double tapping the switch…”, “When holding down the button on a dimmer switch…”, or “When the button is released…” ** Available as a starter only: Single or multi-press / Long press / Long press release One reason Google may have finally made th...
Key Points Wilson Asset Management sold 114,425 shares of BellRing Brands in the fourth quarter. The estimated transaction was valued at about $4.16 million based on last-disclosed values. The position previously accounted for 1.03% of the fund's AUM as of the prior quarter. These 10 stocks could mint the next wave of millionaires › On February 2, Wilson Asset Management reported selling its entir...
Key Points Wilson Asset Management sold 114,425 shares of BellRing Brands in the fourth quarter. The estimated transaction was valued at about $4.16 million based on last-disclosed values. The position previously accounted for 1.03% of the fund's AUM as of the prior quarter. These 10 stocks could mint the next wave of millionaires › On February 2, Wilson Asset Management reported selling its entire stake in BellRing Brands (NYSE:BRBR), disposing of 114,425 shares worth an estimated $4.16 million. What happened According to a Securities and Exchange Commission (SEC) filing dated February 2, Wilson Asset Management eliminated its position in BellRing Brands by selling 114,425 shares. The fund's quarter-end position in BellRing Brands fell by $4.16 million, a figure that factors in both the trade and any stock price movement. What else to know Top holdings after the filing: NASDAQ: GOOGL: $38.09 million (9.8% of AUM) NASDAQ: INTU: $26.77 million (6.9% of AUM) NYSE: PWR: $23.31 million (6.0% of AUM) NYSE: ICE: $20.16 million (5.2% of AUM) NYSE: MSCI: $19.98 million (5.1% of AUM) As of February 2, shares of BellRing Brands were priced at $24.39, down 68.8% over the previous year and vastly underperforming the S&P 500’s roughly 15% gain in the same period. Company overview Metric Value Market Capitalization $2.92 billion Price (as of February 3) $24.39 Revenue (TTM) $2.32 billion Net Income (TTM) $216.20 million Company snapshot BellRing Brands offers ready-to-drink shakes and powder protein products under the Premier Protein and Dymatize brands, with nutrition products as the primary revenue driver. The company operates a branded consumer packaged goods model, generating income through wholesale and retail distribution across club, food, drug, mass, eCommerce, specialty, and convenience channels. It targets health-conscious consumers and fitness enthusiasts in the United States and internationally, distributing products through both physical and online retail partners. B...
This article first appeared on GuruFocus. Palantir Technologies Inc. (NASDAQ:PLTR) delivered an outlook that could reshape near-term investor expectations after a muted start to the year, projecting fiscal 2026 revenue of about $7.19 billion, implying 61% annual growth and landing well above the $6.27 billion consensus. The company also guided current-quarter revenue to roughly $1.53 billion, ahea...
This article first appeared on GuruFocus. Palantir Technologies Inc. (NASDAQ:PLTR) delivered an outlook that could reshape near-term investor expectations after a muted start to the year, projecting fiscal 2026 revenue of about $7.19 billion, implying 61% annual growth and landing well above the $6.27 billion consensus. The company also guided current-quarter revenue to roughly $1.53 billion, ahead of expectations, following a fourth quarter that saw revenue climb 70% to $1.41 billion and earnings per share reach 25 cents versus estimates of 23 cents. Shares rose about 5% in extended trading after closing at $147.77, though the stock remained down 17% year to date and about 29% below its November peak, while still trading at roughly 141 times expected earnings. The quarter pointed to momentum across both sides of Palantir's US business. US government revenue came in at $570 million, exceeding the $521.5 million analysts were expecting, while US commercial revenue reached $507 million compared with a $478.7 million consensus. Speaking after the results, Chief Technology Officer Shyam Sankar said usage of Maven, an AI-enabled mission control system used by the US military, is at an all-time high, with further rollout expected this year. That traction could reinforce Palantir's positioning as one of the most visible public-market beneficiaries of the AI boom, even as its revenue base remains heavily tied to government contracts. At the same time, the broader narrative around Palantir remains complex. The company's work with US Immigration and Customs Enforcement and other agencies has drawn criticism, particularly amid immigration enforcement under US President Donald Trump. In a shareholder letter, Chief Executive Officer and co-founder Alexander Karp described the company's accelerating revenue as a cosmic reward, while arguing its software could help prevent unconstitutional intrusions into citizens' private lives, without specifying how. Investor debate has also be...
Dzmitry Dzemidovich/iStock via Getty Images Year in Review Although bumpy at the outset, 2025 was a great year for stocks and bonds: Some notable market events included President Trump’s inauguration, the announcement of tariffs on nearly all of our global trading partners followed by Liberation Day a week later, a government shutdown, the passage of The One Big Beautiful Bill, Federal Reserve rat...
Dzmitry Dzemidovich/iStock via Getty Images Year in Review Although bumpy at the outset, 2025 was a great year for stocks and bonds: Some notable market events included President Trump’s inauguration, the announcement of tariffs on nearly all of our global trading partners followed by Liberation Day a week later, a government shutdown, the passage of The One Big Beautiful Bill, Federal Reserve rate cuts, and unrest in the streets of Los Angeles Not to be fazed by the headlines, large cap and growth stocks continued to dominate here in the US, up around 18% for the year Weakening of the U.S. dollar drove significant outperformance by international stocks for the first time since 2017. Small cap stocks rallied 14.9% in the second half of the year based primarily on the anticipation of interest rate cuts that began in September, ending the year up 12.8% Lower rates also resulted in strong gains from bonds, with corporate bonds beating Treasuries and longer-term bonds beating short maturities. Short-term Treasuries gained 5.2%, while intermediate-term corporate bonds gained 8%. Portfolio Commentary We came into the year expecting a cooler stock market than what we had seen in 2023-2024, when the market, as measured by the S&P 500, gained 26.3% and 25%, respectively. I suppose we were right, but I think 18% is probably more than we were anticipating. The first quarter appeared to be on track with that forecast as the market declined, with growth stocks hit particularly hard while more defensive areas of the market proved resilient. As March came to a close, we took advantage of more reasonable valuations by reducing our underweight to growth stocks while trimming dividend payers on the heels of a period of relative strength. A few weeks later, in early April, we opportunistically added to equities from bonds as widespread fear and uncertainty over tariff announcements pushed equities well into bear market territory. Fast forward 9 months, the S&P 500 gained over 30% from...
Key Points American Tower is a leading infrastructure REIT. The company's CoreSite data center platform is building AI-enabled data centers. These facilities could provide Wall Street firms with the speed they need. 10 stocks we like better than American Tower › AI stocks have been the hot trade over the past year. That's due to surging demand for chips by companies building AI models and applicat...
Key Points American Tower is a leading infrastructure REIT. The company's CoreSite data center platform is building AI-enabled data centers. These facilities could provide Wall Street firms with the speed they need. 10 stocks we like better than American Tower › AI stocks have been the hot trade over the past year. That's due to surging demand for chips by companies building AI models and applications. However, chips and related hardware are only part of the AI story. Companies need infrastructure to house all this high-tech hardware and transmit all their AI-related data. That plays right into American Tower's (NYSE: AMT) strategy. The infrastructure REIT is quietly building data centers to support AI workloads. In doing so, it's about to become Wall Street's secret weapon. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Hiding in plain sight American Tower is one of the world's largest REITs. It's a leading independent owner, operator, and developer of multitenant communications real estate with a global portfolio of over 149,000 sites. Additionally, it owns a highly interconnected footprint of U.S. data center facilities. The REIT bought its data center platform in 2021 through its $10.1 billion acquisition of CoreSite. The data center REIT owned 25 data centers across eight major U.S. markets. While it was a sizable deal, it wasn't a major deviation from the REIT's strategy. American Tower bought CoreSite to support the accelerating global deployment of 5G networks. The deal followed its $9.4 billion purchase of Telxius Towers earlier in the year and its $3.5 billion purchase of InSite Wireless Group the previous year. 5G was also the primary focus of those tower deals. Building a secret weapon to capitalize on AI While 5G was the initial rationale behind buying CoreSite, the company has since started to leverage its expertise in building data centers to develop facilities for...
Empery Digital ( EMPD ) has announced an increase in its previously authorized share repurchase program from $150M to $200M. As of February 2, 2026, 14.26M shares of the company’s common stock have been repurchased by the company at an average purchase price per share of $6.90. Following this increase, around $102M remains available under the share repurchase program. More on Volcon Empery Digital...
Empery Digital ( EMPD ) has announced an increase in its previously authorized share repurchase program from $150M to $200M. As of February 2, 2026, 14.26M shares of the company’s common stock have been repurchased by the company at an average purchase price per share of $6.90. Following this increase, around $102M remains available under the share repurchase program. More on Volcon Empery Digital: Bitcoin Futures Point To Lack Of Dip Buying Empery Digital announces $150M on share buyback Empery Digital announces update on share repurchase program Seeking Alpha’s Quant Rating on Volcon Financial information for Volcon
Charli XCX wore a see-through black dress at last year's Brit Awards, and addressed the controversy over her outfit during one of her speeches on the night. "I heard that ITV were complaining about my nipples. I feel like we're in the era of 'free the nipple' though, right?" she said.
Charli XCX wore a see-through black dress at last year's Brit Awards, and addressed the controversy over her outfit during one of her speeches on the night. "I heard that ITV were complaining about my nipples. I feel like we're in the era of 'free the nipple' though, right?" she said.
Cipher Mining Inc. is seeking to raise $2 billion in the US junk bond market to help fund construction of a data center tied to Amazon.com Inc. The firm plans to sell notes maturing in 2031 in a private offering to finance the remaining cost of its Black Pearl facility, a computing data center in Wink, Texas, the company said in a statement . The cryptocurrency miner last tapped the high-yield bon...
Cipher Mining Inc. is seeking to raise $2 billion in the US junk bond market to help fund construction of a data center tied to Amazon.com Inc. The firm plans to sell notes maturing in 2031 in a private offering to finance the remaining cost of its Black Pearl facility, a computing data center in Wink, Texas, the company said in a statement . The cryptocurrency miner last tapped the high-yield bond market in November, raising roughly $1.7 billion in debt as part of a push to expand its compute capacity. In November, Cipher signed an agreement to build 300 megawatts of gross data center capacity at the Black Pearl facility that will be leased to Amazon Web Services for at least 15 years.
(RTTNews) - AbbVie (ABBV) on Tuesday said it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of Rinvoq for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The submissions are based on data from the Phase 3 Viti-Up studies, which showed that upadacitinib met the co-primary endpoints of a...
(RTTNews) - AbbVie (ABBV) on Tuesday said it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of Rinvoq for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV). The submissions are based on data from the Phase 3 Viti-Up studies, which showed that upadacitinib met the co-primary endpoints of at least 50% improvement in total body repigmentation and at least 75% improvement in facial repigmentation from baseline at week 48. Rinvoq is a prescription medicine approved for a range of immune-mediated inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis among others. AbbVie shares closed at $225.64 on Monday, up 1.18%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.